Telmisartan improves high glucose and high insulin-induced proliferation of cardiac fibroblasts and its mechanism[J]. Chinese Heart Journal, 2016, 28(4): 380-383.
    Citation: Telmisartan improves high glucose and high insulin-induced proliferation of cardiac fibroblasts and its mechanism[J]. Chinese Heart Journal, 2016, 28(4): 380-383.

    Telmisartan improves high glucose and high insulin-induced proliferation of cardiac fibroblasts and its mechanism

    • AIM To study the effect of telmisartan on high glucose and high insulin induced-proliferation of cardiac fibroblasts and its mechanism. METHODSCardiac fibroblasts of suckling Spargue Dawley rats were cultured and randomly divided into control group (5.5 mmol/L glucose), high glucose and high insulin group (25 mmol/L glucose+1×10-7 mol/L insulin), extracellular regulated protein kinase (ERK) inhibitor group (high glucose and high insulin+10 μmol/L PD98059) and telmisartan group (high glucose and high insulin+10 mol/L telmisartan). Forty-eight hours after culture, cell proliferation was detected with cell counting kit-8 (CCK8), cell numbers were measured using crystal violet staining and DNA synthesis was measured using [3H]thymidine marker. Cell cycle was analyzed using flow cytometry, content of angiotensin II (AngII) and aldosterone (ALD) were measured using ELISA. Protein expression of phosphorylated ERK1/2 (p-ERK1/2) was detected using Western blot. RESULTSCompared with those in control group, cell proliferation (1.43±0.12 vs. 0.50±0.10), cell numbers (1.64±0.03 vs. 1.06±0.02), DNA synthesis (26135.47±324.86 vs. 14528.26±267.18), percentage of S+G2+M [(19.33±0.12) vs.(8.56±0.07)%] content of AngII [(30.58±7.26) vs.(18.26±2.64) pg/ml] and ALD [(19.62±1.25) vs.(12.83±1.29) pg/ml] and protein expression of p-ERK1/2 in high glucose and high insulin group all significantly increased (P<0.05). Compared with those in high glucose and high insulin group, cell proliferation (0.72±0.06 vs. 1.33±0.12), cell numbers (1.35±0.01 vs. 1.64±0.03), DNA synthesis (18643.76±192.52 vs. 26135.47±324.86), percentage of S+G2+M [(12.84±0.36) vs. (19.33±0.12%)] content of AngII [(23.17±5.31) vs.(30.58±7.26) pg/ml] and ALD [(15.27±1.13) vs.(19.62±1.25 pg/ml] and protein expression of p-ERK1/2 in ERK inhibitor group decreased significantly (P<0.05). Compared with those in high glucose and high insulin group, cell proliferation (0.94±0.05 vs. 1.33±0.12), cell numbers (1.49±0.02 vs. 1.64±0.03), DNA synthesis (21829.35±154.73 vs. 26135.47±324.86), percentage of S+G2+M [(15.13±0.42) vs.(19.33±0.12)%] content of AngII [(26.84±4.36) vs.(30.58±7.26) pg/ml] and ALD [(17.81±1.53) vs.(19.62±1.25) pg/ml] and protein expression of p-ERK1/2 significantly decreased (P<0.05). No significant difference was found in the above indexes between ERK inhibitor group and telmisartan group. CONCLUSIONAs the inhibitor of AT1 receptor, telmisartan improves high glucose and high insulin-induced proliferation of cardiac fibroblasts partly through inhibiting the ERK1/2 signaling pathway.
    • loading

    Catalog

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return